Controlled inhalation of THC-predominant cannabis flos mitigates severity of PTSD symptoms and improves quality of sleep and general mood in cannabis-experienced UK civilians: a real-world, observational study.

Medical Cannabis and Cannabinoids, Год журнала: 2024, Номер 7(1), С. 149 - 159

Опубликована: Авг. 28, 2024

Introduction: Approximately 4% of the UK population experiences PTSD. Individuals must exhibit symptoms across four clusters to receive a diagnosis: intrusion, avoidance, altered reactivity, and mood. Evidence suggests that cannabinoid agonists such as nabilone tetrahydrocannabinol (THC) may alleviate PTSD symptoms. We investigated safety effectiveness THC-predominant cannabis flowers for inhalation manage in real-world setting. Methods: analysed data from patient registry, T21. Validated questionnaires were used collect PROMs health-related quality life (HRQoL), mood/anxiety, sleep, PTSD-specific Inclusion criteria (i) confirmed diagnosis PTSD, (ii) completed at baseline 3-month follow-up, (iii) received prescription chemotype 1 (THC-predominant) flower. Results: Fifty-eight patients included, 34 which also had recorded 6 months. Most males (65.5%) with an average age 39.2 years who previously illicitly (95.6%). At 3 months, participants reported significant improvements overall health, mood, sleep (p < 0.001) but not proxy HRQoL = 0.052). Similarly, substantial benefits managing intrusion 0.001), mood alterations reactivity 0.002), sustained or further improved Participants did report any side effects associated CBMPs. Conclusions: Inhalation THC is well tolerated useful cannabis-experienced individuals. However, research needed evaluate long-term outcomes controlled CBMP naïve cannabis.

Язык: Английский

---

Linking Coronary Artery Disease, Posttraumatic Stress Disorder (PTSD), and Genetic Commonality

Опубликована: Янв. 1, 2024

Язык: Английский

---